Open AccessA REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT)
Author(s) -
Sampath Kumar,
Priyank Purohit,
Seema Dagar
Publication year - 2018
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2018.v11i8.26271
Subject(s) - anaplastic lymphoma kinase , lung cancer , cancer research , cancer , epidermal growth factor receptor , oncogene , oncology , medicine , mutation , kinase , targeted therapy , biology , gene , bioinformatics , genetics , cell cycle , malignant pleural effusion
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.